220 related articles for article (PubMed ID: 21316534)
1. Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults.
Chang MH; Kish TD; Fung HB
Clin Ther; 2010 Dec; 32(13):2160-85. PubMed ID: 21316534
[TBL] [Abstract][Full Text] [Related]
2. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
Stryjewski ME; Graham DR; Wilson SE; O'Riordan W; Young D; Lentnek A; Ross DP; Fowler VG; Hopkins A; Friedland HD; Barriere SL; Kitt MM; Corey GR;
Clin Infect Dis; 2008 Jun; 46(11):1683-93. PubMed ID: 18444791
[TBL] [Abstract][Full Text] [Related]
3. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
4. Telavancin: a novel lipoglycopeptide antibiotic.
Charneski L; Patel PN; Sym D
Ann Pharmacother; 2009 May; 43(5):928-38. PubMed ID: 19401479
[TBL] [Abstract][Full Text] [Related]
5. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.
Stryjewski ME; Chu VH; O'Riordan WD; Warren BL; Dunbar LM; Young DM; Vallée M; Fowler VG; Morganroth J; Barriere SL; Kitt MM; Corey GR;
Antimicrob Agents Chemother; 2006 Mar; 50(3):862-7. PubMed ID: 16495243
[TBL] [Abstract][Full Text] [Related]
6. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.
Leonard SN; Rybak MJ
Pharmacotherapy; 2008 Apr; 28(4):458-68. PubMed ID: 18363530
[TBL] [Abstract][Full Text] [Related]
7. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
Stryjewski ME; O'Riordan WD; Lau WK; Pien FD; Dunbar LM; Vallee M; Fowler VG; Chu VH; Spencer E; Barriere SL; Kitt MM; Cabell CH; Corey GR;
Clin Infect Dis; 2005 Jun; 40(11):1601-7. PubMed ID: 15889357
[TBL] [Abstract][Full Text] [Related]
8. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin resistance: are there better glycopeptides coming?
Linden PK
Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
[TBL] [Abstract][Full Text] [Related]
10. Dalbavancin: a new option for the treatment of gram-positive infections.
Lin SW; Carver PL; DePestel DD
Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792
[TBL] [Abstract][Full Text] [Related]
12. Telavancin: a novel lipoglycopeptide.
Saravolatz LD; Stein GE; Johnson LB
Clin Infect Dis; 2009 Dec; 49(12):1908-14. PubMed ID: 19911938
[TBL] [Abstract][Full Text] [Related]
13. Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results.
Putnam SD; Sader HS; Moet GJ; Mendes RE; Jones RN
Diagn Microbiol Infect Dis; 2010 Aug; 67(4):359-68. PubMed ID: 20638605
[TBL] [Abstract][Full Text] [Related]
14. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.
Zhanel GG; Trapp S; Gin AS; DeCorby M; Lagacé-Wiens PR; Rubinstein E; Hoban DJ; Karlowsky JA
Expert Rev Anti Infect Ther; 2008 Feb; 6(1):67-81. PubMed ID: 18251665
[TBL] [Abstract][Full Text] [Related]
15. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures.
Wilson SE; O'Riordan W; Hopkins A; Friedland HD; Barriere SL; Kitt MM;
Am J Surg; 2009 Jun; 197(6):791-6. PubMed ID: 19095213
[TBL] [Abstract][Full Text] [Related]
16. Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
Laohavaleeson S; Kuti JL; Nicolau DP
Expert Opin Investig Drugs; 2007 Mar; 16(3):347-57. PubMed ID: 17302529
[TBL] [Abstract][Full Text] [Related]
17. Telavancin: a new lipoglycopeptide with multiple mechanisms of action.
Kanafani ZA
Expert Rev Anti Infect Ther; 2006 Oct; 4(5):743-9. PubMed ID: 17140351
[TBL] [Abstract][Full Text] [Related]
18. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
Das B; Sarkar C; Biswas R; Pandey S
Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
[TBL] [Abstract][Full Text] [Related]
19. Telavancin (Vibativ) for gram-positive skin infections.
Med Lett Drugs Ther; 2010 Jan; 52(1329):1-2. PubMed ID: 20208468
[No Abstract] [Full Text] [Related]
20. Tigecycline: a novel glycylcycline antibiotic.
Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
